Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cyclacel Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Cyclacel Pharmaceuticals, Inc.’s stock price such as:

Cyclacel Pharmaceuticals, Inc.’s current stock price and volume
Why Cyclacel Pharmaceuticals, Inc.’s stock price changed recently
Upgrades and downgrades for CYCC from analysts
CYCC’s stock price momentum as measured by its relative strength

About Cyclacel Pharmaceuticals, Inc. (CYCC)

Before we jump into Cyclacel Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Want to learn more about Cyclacel Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cyclacel Pharmaceuticals, Inc..

Cyclacel Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of April 28, 2025, 12:30 PM, CST, Cyclacel Pharmaceuticals, Inc.’s stock price was $0.307.

Cyclacel Pharmaceuticals, Inc. is up 10.16% from its previous closing price of $0.279.

During the last market session, Cyclacel Pharmaceuticals, Inc.’s stock traded between $0.280 and $0.340. Currently, there are approximately 9.24 million shares outstanding for Cyclacel Pharmaceuticals, Inc..

Cyclacel Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cyclacel Pharmaceuticals, Inc. Stock Price History

Cyclacel Pharmaceuticals, Inc.’s (CYCC) price is currently up 9.89% so far this month.

During the month of April, Cyclacel Pharmaceuticals, Inc.’s stock price has reached a high of $0.340 and a low of $0.171.

Over the last year, Cyclacel Pharmaceuticals, Inc. has hit prices as high as $4.000 and as low as $0.171. Year to date, Cyclacel Pharmaceuticals, Inc.’s stock is down 18.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cyclacel Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 25, 2025, there were analysts who downgraded Cyclacel Pharmaceuticals, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cyclacel Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cyclacel Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cyclacel Pharmaceuticals, Inc. (CYCC) by visiting AAII Stock Evaluator.

Relative Price Strength of Cyclacel Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 25, 2025, Cyclacel Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -35.70%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how Cyclacel Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cyclacel Pharmaceuticals, Inc. Stock Price: Bottom Line

As of April 28, 2025, Cyclacel Pharmaceuticals, Inc.’s stock price is $0.307, which is up 10.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cyclacel Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.